|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.16 USD | +1.44% |
|
-3.68% | -7.10% |
| 05-24 | Recursion Names HilleVax CEO Robert Hershberg as New Board Chair | MT |
| 05-13 | Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed | MT |
Recursion Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 13.49 million compared to USD 12.13 million a year ago. Revenue was USD 13.79 million compared to USD 12.13 million a year ago.
Net loss was USD 91.37 million compared to USD 65.33 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.34 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.10% | 2.15B | |
| +12.30% | 116B | |
| +12.15% | 106B | |
| -8.14% | 23.89B | |
| -1.69% | 21.58B | |
| -10.60% | 18.96B | |
| -41.25% | 16.96B | |
| -15.33% | 16.33B | |
| +5.80% | 14.14B | |
| +28.03% | 12.02B |
RECURSION PHARMACEUTICALS, INC. 
